Caribou Biosciences, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Caribou reported Q2 2026 net loss of $24.3M ($0.24/share) on revenue of $1.5M. Phase 1 data for vispa-cel (anti-CD19 CAR-T) showed 82% ORR and 67% CR in 27 optimized 2L LBCL patients; CB-011 (anti-BCMA CAR-T) showed 92% ORR and 83% CR in 12 BCMA-naïve MM patients. Cash position declined to $113.8M (from $142.8M at year-end 2025); company expects runway to end of 2027 but is exploring additional funding for planned ANTLER-3 pivotal phase 3 trial (~250 patients). Q2 R&D expenses were $18.9M (down from $27.7M YoY) and G&A was $7.9M (down from $10.4M YoY) following April 2025 workforce reduction.
Why this rating
Positive clinical data on two lead programs de-risks pipeline and supports regulatory path, but cash burn and near-term funding need for pivotal trial present material risk. Event is moderate-to-significant for ~$113M market-cap biotech.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.